Loading...
Loading...
BOSTON, MA · CIK 0001346824
New positions
17
Added to
10
Trimmed
10
Exited
18
Source: SEC 13F-HR filing filed on 2026-08-14 ·View on SEC.gov →
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | $2.74B | 23.83% | New |
| 2 | PBLSPARABILIS MEDICINES INC | $791.91M | 6.88% | New |
| 3 | RYTMRHYTHM PHARMACEUTICALS INC | $740.22M | 6.43% | - |
| 4 | PCVXVAXCYTE INC | $667.02M | 5.80% | - |
| 5 | SIONSIONNA THERAPEUTICS INC | $435.72M | 3.79% | - |
| 6 | TYRATYRA BIOSCIENCES INC | $389.62M | 3.39% | - |
| 7 | EWTXEDGEWISE THERAPEUTICS INC | $341.00M | 2.96% | -19.5% |
| 8 | NAMSNEWAMSTERDAM PHARMA CO NV | $323.66M | 2.81% | - |
| 9 | COAGHEMAB THERAPEUTICS HOLDINGS | $286.81M | 2.49% | New |
| 10 | SEPNSEPTERNA INC | $234.29M | 2.04% | - |
| Stock | Value | Shares |
|---|---|---|
| ASCENDIS PHARMA A/S | $2.74B | 10,281,496 |
| PBLSPARABILIS MEDICINES INC | $791.91M | 28,933,371 |
| COAGHEMAB THERAPEUTICS HOLDINGS | $286.81M | 7,808,627 |
| ABVXABIVAX SA-ADR | $150.92M | 1,132,557 |
| ORKAORUKA THERAPEUTICS INC | $147.95M | 1,554,597 |
| NTLAINTELLIA THERAPEUTICS INC | $76.60M | 4,526,926 |
| DFTXDEFINIUM THERAPEUTICS INC | $70.56M | 1,500,000 |
| SANASANA BIOTECHNOLOGY INC | $65.44M | 18,750,000 |
| PRLDPRELUDE THERAPEUTICS INC | $34.52M | 6,475,882 |
| QTTBQ32 BIO INC | $29.72M | 2,332,457 |
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. reported a portfolio value of $11.51B across 84 positions in their 13F filing.
RA CAPITAL MANAGEMENT, L.P.'s largest holding is ASCENDIS PHARMA A/S with a position worth $2.74B. Their top holdings include ASCENDIS PHARMA A/S, PBLS, RYTM, PCVX, SION.
In Q2 2026, RA CAPITAL MANAGEMENT, L.P. made the following changes to their portfolio: 17 new positions, 18 positions sold out, 10 positions increased, 10 positions reduced.
RA CAPITAL MANAGEMENT, L.P. files quarterly 13F reports with the SEC, disclosing their long positions in U.S. equities. These filings are due within 45 days of the quarter end and provide transparency into their investment strategy and portfolio allocation.
Get alerts when RA CAPITAL MANAGEMENT, L.P. files new 13F holdings.